Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
ADC TherapeuticsADCT | Open-market sale | 03/31–04/02 | 04/02 | 5,880,415 sh6 trades | $3.34avg. | $19,641,066.76 | No record | |
ADC TherapeuticsADCT | Open-market buy | 24/12/11 | 24/12/13 | 200,000 sh4 trades | $3.05avg. | $609,000 | No record | |
Redmile Group10% Owner | ADC TherapeuticsADCT | Open-market sale | 24/12/04 | 24/12/06 | 25,352 sh | $2.07 | $52,478.64 | −0.2% |
ADC TherapeuticsADCT | Open-market buy | 24/07/01 | 24/07/03 | 800,000 sh2 trades | $2.81avg. | $2,248,000 | No record | |
Ron SquarerDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 6,995 sh | $2.89 | $20,215.55 | −8.0% |
Victor SandorDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 6,995 sh | $2.89 | $20,215.55 | −8.0% |
Jean-Pierre BizzariDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 6,995 sh | $2.89 | $20,215.55 | −8.1% |
Robert AzelbyDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 6,995 sh | $2.89 | $20,215.55 | −11.7% |
Thomas PfistererDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 1,437 sh | $2.89 | $4,152.93 | −0.7% |
Viviane MongesDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 1,437 sh | $2.89 | $4,152.93 | −1.3% |
Peter HugDirector | ADC TherapeuticsADCT | Open-market sale | 24/06/17 | 24/06/18 | 1,193 sh | $2.89 | $3,447.77 | −0.6% |
Ameet MallikCEO | ADC TherapeuticsADCT | Open-market sale | 24/05/07 | 24/05/09 | 29,731 sh | $4.48 | $133,194.88 | −2.5% |
